Teva Pharmaceutical Industries Ltd. ADR 1.14% $25.35B ...

GSK's experimental IL-5 inhibitor depemokimab ... Reimagining What's Possibl In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours ...

GSK, its consumer health spin-off Haleon ... Reimagining What's Possibl In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of £16.90. The company’s shares closed today at p1,321. ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at p1,388.50. Pick the best stocks and maximize ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

UK-based GlaxoSmithKline PLC (GB:GSK) hits a key milestone in its ovarian cancer trial, testing Zejula (niraparib) and Jemperli (dostarlimab). The company announced that its FIRST-ENGOT-OV44 phase ...